Avestar Capital LLC Acquires New Position in Shire PLC (SHPG)
Avestar Capital LLC acquired a new stake in shares of Shire PLC (NASDAQ:SHPG) during the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 851 shares of the biopharmaceutical company’s stock, valued at approximately $116,000.
Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Brandywine Global Investment Management LLC acquired a new stake in Shire in the 4th quarter worth about $41,763,000. Argentiere Capital AG boosted its stake in Shire by 15.0% in the 4th quarter. Argentiere Capital AG now owns 23,000 shares of the biopharmaceutical company’s stock worth $3,568,000 after buying an additional 3,000 shares during the last quarter. Aristotle Atlantic Partners LLC acquired a new stake in Shire in the 4th quarter worth about $2,852,000. Highland Capital Management LP boosted its stake in Shire by 24.3% in the 4th quarter. Highland Capital Management LP now owns 39,765 shares of the biopharmaceutical company’s stock worth $6,168,000 after buying an additional 7,765 shares during the last quarter. Finally, Prisma Capital Partners LP acquired a new stake in Shire in the 4th quarter worth about $7,368,000. 19.75% of the stock is currently owned by institutional investors and hedge funds.
SHPG has been the topic of a number of research analyst reports. Cantor Fitzgerald set a $222.00 price target on Shire and gave the stock a “buy” rating in a research note on Tuesday, December 5th. Royal Bank of Canada reissued a “buy” rating on shares of Shire in a research note on Thursday, November 16th. Liberum Capital raised Shire from a “hold” rating to a “buy” rating in a research note on Tuesday, November 14th. Cowen set a $225.00 price target on Shire and gave the stock a “buy” rating in a research note on Friday, January 5th. Finally, Bank of America raised their price target on Shire from $236.00 to $237.00 and gave the stock a “buy” rating in a research note on Monday, February 5th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $204.00.
Shire (NASDAQ:SHPG) last released its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported $3.98 EPS for the quarter, topping analysts’ consensus estimates of $3.86 by $0.12. The company had revenue of $4.14 billion for the quarter. Shire had a return on equity of 14.19% and a net margin of 28.17%. The business’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter last year, the business earned $3.37 earnings per share. equities research analysts anticipate that Shire PLC will post 15.23 earnings per share for the current year.
The business also recently announced a semiannual dividend, which will be paid on Tuesday, April 24th. Investors of record on Friday, March 9th will be issued a dividend of $0.8937 per share. This is an increase from Shire’s previous semiannual dividend of $0.15. This represents a dividend yield of 1.33%. The ex-dividend date of this dividend is Thursday, March 8th. Shire’s dividend payout ratio (DPR) is presently 17.30%.
ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2018/03/14/avestar-capital-llc-acquires-new-position-in-shire-plc-shpg.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.